



* These recommendations are intended as guidelines only. Clinical judgment must be used in decision making regarding treatment and testing of the thrombocytopenic patient. Hematology consultation is available for management of patients with uncertain diagnosis or significant bleeding risks.

Name	DIRECT THROMBIN INHIBITOR OPTIONS			OTHER OPTIONS
	BIVALIRUDIN	ARGATROBAN	LEPIRUDIN	FONDAPARINUX
Status	First line agent for inpatients with/without thrombosis	Second line agent for inpatients with/without thrombosis NON-FORMULARY	Second line agent for inpatients with/without thrombosis NON-FORMULARY	First line agent for outpatients without thrombosis only. NON-FORMULARY
Initial dose	0.15mg/kg/hr	2mcg/kg/min (0.5-1.2 mcg/kg/min in pts with heart failure, multi-organ system failure, severe anasarca or post-cardiac surgery)	0.1mg/kg/hr (with 0.2mg/kg bolus in pts with life- or limb-threatening thrombosis)	Wt. <50kg : 5mg SQ qd Wt 50-100kg: 7.5mg SQ qd Wt >100kg 10mg SQ qd
Dosing in renal impairment	Consult pharmacy if CLCR <60ml/min	No adjustment needed	Consult pharmacy if CLCR <60ml/min	CONTRAINDICATED if CLCR <60nl/min
Dosing in Hepatic Failure	No adjust. needed	Consult pharmacy	No adjust. needed	No adjust. needed
Goal aPTT	60-80 seconds	60-80 seconds	60-80 seconds	No monitoring required
Goal DTI Assay	60-90 seconds	60-100 seconds	90-160 seconds	N/A
First aPTT after initiation	2 hours	2 hours	4 hours	No monitoring required
Effect on INR	moderate	profound	moderate	minimal
* Hold DTI before checking INR	2 hours	4 hours	4 - 8 hours	N/A

* These recommendations are intended as guidelines only. Clinical judgment must be used in decision making regarding treatment and testing of the thrombocytopenic patient. Hematology consultation is available for management of patients with uncertain diagnosis or significant bleeding risks.